D. E. Shaw & Co. Inc. Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

D. E. Shaw & Co. Inc. increased its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 283.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,114 shares of the company’s stock after buying an additional 51,823 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.11% of Monte Rosa Therapeutics worth $487,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Versant Venture Management LLC acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at about $39,231,000. BVF Inc. IL purchased a new position in Monte Rosa Therapeutics during the fourth quarter valued at approximately $19,185,000. Vanguard Group Inc. lifted its holdings in Monte Rosa Therapeutics by 24.5% in the fourth quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company’s stock valued at $21,905,000 after acquiring an additional 622,134 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Monte Rosa Therapeutics by 7.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company’s stock valued at $49,391,000 after acquiring an additional 515,496 shares during the period. Finally, Norges Bank purchased a new stake in Monte Rosa Therapeutics in the 4th quarter worth approximately $3,094,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Trading Down 2.0%

Shares of GLUE opened at $3.97 on Monday. The firm has a market capitalization of $244.19 million, a price-to-earnings ratio of -2.17 and a beta of 1.52. The firm’s fifty day simple moving average is $4.59 and its 200-day simple moving average is $6.21. Monte Rosa Therapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $12.40.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.81. The company had revenue of $84.93 million for the quarter, compared to analysts’ expectations of $13.57 million. On average, analysts predict that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Chandra P. Leo bought 10,000 shares of the business’s stock in a transaction on Monday, March 24th. The stock was bought at an average price of $5.84 per share, for a total transaction of $58,400.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $58,400. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on GLUE shares. Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday, March 21st. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price target (up previously from $15.00) on shares of Monte Rosa Therapeutics in a report on Thursday, March 20th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Lifesci Capital started coverage on Monte Rosa Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $19.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.